[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351718-105":59,"doc-detail-351718-en":135},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":128,"head_meta":130,"extra_data":132,"updated_unix":134},105,"en","secondary-primary-tumors-following-iodine-125-low-dose-rate-brachytherapy-for-localized-prostate-cancer","Secondary primary tumors following iodine-125 low-dose-rate brachytherapy for localized prostate cancer","","Low-dose-rate brachytherapy with iodine-125 is a curative radiation option for localized prostate cancer, yet long-term secondary primary tumor (SPT) risk remains insufficiently characterized. This retrospective study evaluated 478 Japanese patients treated with LDR-BT at Gifu University Hospital, focusing on SPT incidence as the primary endpoint and on predictive factors as the secondary endpoint. After 105 months median follow-up, SPTs occurred in 2.7% overall. Multivariate analysis linked biologically effective dose (BED) ≥197 Gy with higher SPT risk, supporting careful long-term surveillance.",{"@graph":69,"@context":127},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/secondary-primary-tumors-following-iodine-125-low-dose-rate-brachytherapy-for-localized-prostate-cancer/351718/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/secondary-primary-tumors-following-iodine-125-low-dose-rate-brachytherapy-for-localized-prostate-cancer/351718.png","ImageObject",300,407,{"name":92,"@type":93},"Stanford","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119,123],{"name":110,"@type":111,"acceptedAnswer":112},"What was the primary aim of this study?","Question",{"text":113,"@type":114},"To evaluate the long-term incidence of secondary primary tumors (SPTs) after iodine-125 low-dose-rate brachytherapy (LDR-BT) and to identify predictive factors associated with SPT development.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How many patients developed secondary primary tumors, and what follow-up duration was used?",{"text":118,"@type":114},"SPTs developed in 13 of 478 patients (2.7%) after a median follow-up of 105 months.",{"name":120,"@type":111,"acceptedAnswer":121},"Which factor was associated with increased SPT risk in multivariate analysis?",{"text":122,"@type":114},"A biologically effective dose (BED) of at least 197 Gy was associated with increased SPT risk (hazard ratio 4.145; p = 0.035).",{"name":124,"@type":111,"acceptedAnswer":125},"Which cancer types were observed among the SPT cases?",{"text":126,"@type":114},"Bladder cancer and rectal/anal canal cancer were observed in seven (1.5%) and six (1.3%) patients, respectively.","https://schema.org",{"og:url":83,"og:type":129,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":131,"canonical":83},"index,follow",{"doc_id":133,"site_id":62},351718,1790212021,{"code":4,"msg":5,"data":136},{"doc_id":133,"user_id":137,"nickname":92,"user_avatar":138,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},2336477552062,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","International Journal of Clinical Oncology (2026) 31:1008–1016  \n[https://doi.org/10.1007/s10147-026-03020-3](https://doi.org/10.1007/s10147-026-03020-3)  \nSecondary primary tumors following iodine‑125 low‑dose‑rate brachytherapy for localized prostate cancer  \nKojiro Niwa1 · Koji Iinuma1 · Masahiro Nakano2 · Masayuki Tomioka1 · Masaya Ito3 · Takayuki Mori3 · Kota Kawase1 · Tomoki Taniguchi1 · Yuki Tobisawa1 · Keita Nakane1 · Masayuki Matsuo3 · Takuya Koie1  \nReceived: 21 January 2026 / Accepted: 18 March 2026 / Published online: 29 March 2026 © The Author(s) 2026  \nAbstract  \nBackground Low-dose-rate brachytherapy with iodine-125 (LDR-BT) is an established curative radiation treatment modality for localized prostate cancer (PCa). This study aimed to evaluate the long-term incidence of secondary primary tumors (SPTs) following LDR-BT in Japanese patients with localized PCa and identify predictive factors associated with SPTs. Methods and materials We retrospectively reviewed the clinical records of 478 consecutive patients with localized PCa who underwent LDR-BT at the Gifu University Hospital. This study’s primary endpoint was SPTs incidence, including bladder and rectal/anal cancers. The secondary endpoint was the identification of risk factors for LDR-BT that predicted SPTs development.  \nResults After a median follow-up period of 105 months, SPTs developed in 13 patients (2.7%) . Bladder cancer and rectal/ anal canal cancer were observed in seven (1.5%) and six (1.3%) patients, respectively. Multivariate analysis showed that a biologically effective dose (BED) ≥ 197 Gy was associated with increased risk of SPTs (hazard ratio 4.145; 95% confidence interval 1.108–15.498; p = 0.035) .  \nConclusions The incidence of SPTs following LDR-BT was relatively low. In multivariate analysis, BED ≥ 197 Gy may be associated with an increased risk of SPT occurrence. Adequate tumor control can be achieved through appropriate radiation dose administration; carefully planned long-term follow-up may be beneficial for SPTs early detection.  \nKeywords Prostate cancer · Low-dose-rate brachytherapy · Secondary primary tumor · Biologically effective dose · Late toxicity  \nIntroduction  \nProstate cancer (PCa) is one of the most common malignancies among men worldwide and in Japan [1, 2] . Definitive treatment modalities for localized PCa, including active surveillance, surgical intervention, and radiation therapy (RT), have demonstrated favorable oncological outcomes worldwide [2] .  \n* Koji Iinuma [iinuma.koji.s0@f.gifu-u.ac.jp](iinuma.koji.s0@f.gifu-u.ac.jp)  \n1 Department of Urology, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu, Gifu 501-1194, Japan  \n2 Department of Urology, Gifu Prefectural General Medical Center, 4-6-1 Noisiki, Gifu, Gifu 500-8717, Japan  \n3 Department of Radiology, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu, Gifu 501-1194, Japan  \nThe low-dose-rate brachytherapy with iodine-125 (LDR-BT), which is used in combination with or without external beam radiation therapy (EBRT), is one of the most effective treatment modalities for RT [3] . LDR-BT generally yields favorable oncological outcomes [4–6] . Previous studies from our institution demonstrated excellent long-term oncological outcomes after LDR-BT [4–6] . A median follow-up period of 90.0 months revealed a 10 year biochemical recurrence (BCR)-free rate of 95.3%  \n[6] . Notably, the 10 year BCR-free rate maintained a high level of 93.4% among patients with PCa categorized as high-risk according to the D’Amico classification [6 , 7] . Although LDR-BT is an effective treatment for long-term cancer control, there are still significant treatment-related toxicities, including radiation-related late complications involving the genitourinary and gastrointestinal organs, including secondary primary tumors (SPTs) following LDR-BT. SPTs are generally defined as occurring > five  \nyears after receiving RT [10–12] . This critical complication sho","cbCaig9ZbScw6lqn","https://ap.wps.com/l/cbCaig9ZbScw6lqn","pdf",852291,"English","# Abstract\n## Background\n## Methods and materials\n## Results\n## Conclusions\n# Introduction\n# Materials and methods\n## Patients","[{\"question\":\"What was the primary aim of this study?\",\"answer\":\"To evaluate the long-term incidence of secondary primary tumors (SPTs) after iodine-125 low-dose-rate brachytherapy (LDR-BT) and to identify predictive factors associated with SPT development.\"},{\"question\":\"How many patients developed secondary primary tumors, and what follow-up duration was used?\",\"answer\":\"SPTs developed in 13 of 478 patients (2.7%) after a median follow-up of 105 months.\"},{\"question\":\"Which factor was associated with increased SPT risk in multivariate analysis?\",\"answer\":\"A biologically effective dose (BED) of at least 197 Gy was associated with increased SPT risk (hazard ratio 4.145; p = 0.035).\"},{\"question\":\"Which cancer types were observed among the SPT cases?\",\"answer\":\"Bladder cancer and rectal/anal canal cancer were observed in seven (1.5%) and six (1.3%) patients, respectively.\"}]","Secondary primary tumors following iodine-125 low-dose-rate brachytherapy for localized prostate cancer | PDF",1790095498,23,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cb07c8f3eacfe255866ced26f1a1dbe9.webp",983,1305,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b08ea493a85eb6fab8e265b0513ae6fc.webp",982,1304,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1804a28e7ba82a2fd563d868fd6c6195.webp",981,1303,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/84955d840e6a55d31044aedee6b701bc.webp",980,1301]